Pricing Log in Create free account

Beam Therapeutics Inc. (BEAM) vs Viridian Therapeutics, Inc. (VRDN)

Beam Therapeutics Inc. and Viridian Therapeutics, Inc. are both Biotechnology companies. Viridian Therapeutics, Inc. is the larger, with a market value of $3.2B against $2.7B — 1.2× the size. Beam Therapeutics Inc. grew revenue faster over the last twelve months: 163.3% against −62.8%. Beam Therapeutics Inc. has the higher net margin (−73.9% vs −1,724.1%) and the lower return on invested capital (−2,676.9% vs 0.00%). Across the 17 metrics below, Beam Therapeutics Inc. leads on 11 and Viridian Therapeutics, Inc. on 6.

Valuation

Metric BEAM VRDN Biotechnology median
P/E n/m n/m 10.26
P/S 18.63 117.81 9.18
P/B 2.87 5.49 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 12.20 91.03 8.98
Earnings yield (3.85%) (11.73%) (34.89%)
Free cash flow yield (14.57%) (11.08%) (24.52%)

Profitability

Metric BEAM VRDN Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (267.68%) (1,781.38%) 0.00%
Net margin (73.89%) (1,724.06%) 0.00%
Free cash flow margin (271.57%) (1,305.42%) 0.00%
Return on equity (11.29%) 0.00% (50.12%)
Return on assets (8.40%) (56.49%) (45.60%)
Return on invested capital (2,676.86%) 0.00% 0.00%

Growth

Metric BEAM VRDN Biotechnology median
Revenue growth (TTM) 163.27% (62.83%) 6.26%
EPS growth (last fiscal year) 82.31% (8.14%) 29.88%
Revenue growth, 5-year CAGR 466.27% 132.18% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM VRDN Biotechnology median
Debt to equity 0.11 0.00 0.00
Current ratio 13.00 14.46 4.89
Net debt to EBITDA 3.30 2.23 1.01

Dividend

Metric BEAM VRDN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BEAM VRDN Biotechnology median
Market cap 2.68b 3.23b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack